September 8, 2009 – Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, said last week it received $36 million in financing to fund the European commercialization and U.S. premarket approval (PMA) clinical study of the company’s TactiCath force-sensing ablation catheter.
Edmond de Rothschild Investment Partners (EdRIP) led the round, with additional participation from Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.
“We believe that Endosense’s TactiCath is uniquely positioned to greatly improve the treatment of cardiac arrhythmias, a series of life-threatening disorders that affect millions of patients worldwide,” said Dr. Olivier Litzka, partner at EdRIP. “Ablation is one of the highest-growth markets in the cardiovascular space. Force measurement during the ablation procedure has become a prime object of interest to improve safety and efficacy for patients. As Endosense with its proprietary force-sensing technology is the clear leader in this field, this represents an excellent investment opportunity to us.”
Granted the CE mark in May 2009, Endosense’s TactiCath is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. The company said the TactiCath has the potential to improve the effectiveness, safety and reproducibility of catheter ablation treatment of cardiac rhythm disorders, including atrial fibrillation (AF). AF is the most common cardiac rhythm disorder today, affecting more than 6 million people worldwide. Currently, most AF patients are treated with pharmaceutical drugs that do not address the underlying cause and have side effects, with invasive ablation surgery as the primary treatment alternative.
For more information: www.endosense.com
October 13, 2025 
